Corvus Pharmaceuticals (CRVS) Long-Term Deferred Tax (2016 - 2022)

Corvus Pharmaceuticals' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $54.9 million for Q4 2019.

• In Q4 2019, Long-Term Deferred Tax rose 74.02% year-over-year to $54.9 million; the TTM figure through Dec 2019 stood at $54.9 million (up 74.02% YoY), while the FY2019 annual figure was $54.9 million, up 74.02% from the prior year.
• Long-Term Deferred Tax for Q4 2019 stood at $54.9 million, up from $31.5 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $54.9 million in Q4 2019, with the low at $9.3 million in Q4 2016.
• The 4-year median for Long-Term Deferred Tax is $23.5 million (2017), against an average of $27.8 million.
• The sharpest annual moves came in 2017 and 2018: Long-Term Deferred Tax jumped 65.31% in 2017, then jumped 104.26% in 2018.
• Corvus Pharmaceuticals' Long-Term Deferred Tax stood at $9.3 million in 2016, then jumped by 65.31% to $15.4 million in 2017, then jumped by 104.26% to $31.5 million in 2018, then jumped by 74.02% to $54.9 million in 2019.
• Business Quant data shows CRVS's Long-Term Deferred Tax at $54.9 million in Q4 2019, $31.5 million in Q4 2018, and $15.4 million in Q4 2017.